Patient education is no longer an optional aspect of pharmaceutical marketing—it is central to commercial success. … Why Patient Education Is Critical for Pharma Commercial SuccessRead more
How Lack of Physician Trust Delays Drug Adoption
Physician trust is the cornerstone of successful drug adoption. Even therapies with superior efficacy or safety … How Lack of Physician Trust Delays Drug AdoptionRead more
Why Traditional Pharma Marketing No Longer Works
The pharmaceutical industry has historically relied on a predictable playbook for bringing new therapies to market. … Why Traditional Pharma Marketing No Longer WorksRead more
How Marketing and Medical Affairs Can Work Better Together
In the modern pharmaceutical landscape, few internal relationships are as strategically important as the one between … How Marketing and Medical Affairs Can Work Better TogetherRead more
Why Pharma Companies Fail at Go-To-Market Execution
In the pharmaceutical industry, few moments are as consequential as the transition from regulatory approval to … Why Pharma Companies Fail at Go-To-Market ExecutionRead more
How Sales Strategy Impacts Drug Adoption After Approval
A drug can clear the U.S. Food and Drug Administration, secure a label, and still stall … How Sales Strategy Impacts Drug Adoption After ApprovalRead more
Why Drugs Fail After Phase I in the U.S. Market
In the United States, roughly 12 percent of drugs that enter clinical testing ultimately receive approval … Why Drugs Fail After Phase I in the U.S. MarketRead more
Why Clinical Trial Data Fails to Translate Into Market Success
A therapy can clear Phase III, secure FDA approval, and generate headline optimism-only to miss revenue … Why Clinical Trial Data Fails to Translate Into Market SuccessRead more
How Poor Communication Between Teams Slows Drug Development
Drug development is often framed as a scientific challenge. Breakthroughs hinge on molecular discovery, biomarker validation, … How Poor Communication Between Teams Slows Drug DevelopmentRead more
Why Regulatory Delays Are Only Part of the U.S. Clinical Trial Problem
When a development program misses projected timelines, the explanation often centers on regulatory review. FDA feedback … Why Regulatory Delays Are Only Part of the U.S. Clinical Trial ProblemRead more